MassDevice is liveblogging the MassMEDIC 11th Annual Medtech Investors Conference. We’re talking to the officers and executives of some of the hottest under-the-radar medical device firms around, finding out how and why their technologies will separate them from the pack.

Prochon Biotech Ltd., Woburn, Mass.

Prochon Biotech is developing a system to regenerate cartilage in knees using cell regeneration technologies, proprietary growth factors and biocompatible scaffolds.

Officers
Patrick T. O’Donnell, CEO
Kirk Andriano, Chief Technical Officer
Avner Yayon, CSO
Kevin McArdle, CFO

Product
Commercially available in Israel, Italy and Greece, the BioCart Autologous Cartilage Regeneration System combines cell regeneration technologies with proprietary growth factors and biocompatible scaffolds to fully restore injured or chronically damaged tissues that resulted from knee injuries. The BioCart System is currently undergoing a Phase II FDA multicenter clinical study. The product has been implanted in more than 70 patients, including elite athletes, as well as 10 patients five years post-surgery.